US 12,084,437 B2
Halo-substituted piperidines as orexin receptor modulators
Theodore M. Kamenecka, Palm Beach Gardens, FL (US); Jörg Holenz, Bolton, MA (US); Steven Wesolowski, Natick, MA (US); Yuanjun He, Palm Beach Gardens, FL (US); and Roland Bürli, Hertfordshire (GB)
Assigned to ASTRAZENECA AB, Södertälje (SE); and EOLAS THERAPEUTICS, INC, Carlsbad, CA (US)
Filed by AstraZeneca AB, Södertälje (SE); and EOLAS THERAPEUTICS, INC., Carlsbad, CA (US)
Filed on Jul. 20, 2022, as Appl. No. 17/868,856.
Application 17/868,856 is a continuation of application No. 17/116,773, filed on Dec. 9, 2020, granted, now 11,434,236.
Application 17/116,773 is a continuation of application No. 16/076,818, granted, now 10,894,789, issued on Jan. 19, 2021, previously published as PCT/US2017/017408, filed on Feb. 10, 2017.
Claims priority of provisional application 62/294,940, filed on Feb. 12, 2016.
Claims priority of provisional application 62/336,102, filed on May 13, 2016.
Prior Publication US 2022/0380359 A1, Dec. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/506 (2006.01); A61P 25/34 (2006.01); C07D 401/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01)
CPC C07D 417/14 (2013.01) [A61P 25/34 (2018.01); C07D 401/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01)] 4 Claims
 
1. A pharmaceutical composition comprising (a) Compound 217,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and (b) a pharmaceutically acceptable excipient.